US › Healthcare

Profound Medical Corp (PROF)

US · Healthcare · Medical Devices

$5.89+1.03%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$2.5M

Revenue YoY

+12.3%

Net profit

$-9.5M

EPS

$0.26

EPS estimate

$-0.22

Net margin

-384.2%

EPS came in at 0.26 against a street estimate of -0.22 — a beat of 218.2%.

Key statistics

Market cap

$218.1M

Forward P/E

0.0

P/B

4.37

Book value

$1.36

EPS (TTM)

$-1.00

52-week high

$8.95

52-week low

$3.90

50-day MA

$7.06

200-day MA

$6.91

Beta

0.50

Analyst view

Analysts rate Profound Medical Corp a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.14.

Shareholding

Insiders

4.06%

Institutions

45.01%

Largest institutional holders

Fund	Stake
Fidelity International Ltd	6.40%
Gagnon Securities LLC	5.36%
Royce & Associates, LP	3.06%
Timelo Investment Management Inc.	3.05%
Gagnon Advisors, LLC	2.63%
Letko, Brosseau & Associates Inc.	2.56%
Arnhold & S. Bleichroeder Advisers, LLC	2.41%
Rosalind Advisors, Inc.	2.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Profound Medical Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.